Open AccessOutcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
Author(s) -
Giovanni Damiani,
Chiara Franchi,
P. D. Pigatto,
Andrea Altomare,
Alessia Pacifico,
Stephen Petrou,
Sebastiano Leone,
Maria Caterina Pace,
Marco Fiore
Publication year - 2018
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v10.i2.329
Subject(s) - medicine , psoriasis , ribavirin , pegylated interferon , dermatology life quality index , hepatitis c virus , psoriasis area and severity index , combination therapy , hepatitis c , gastroenterology , antiviral therapy , dermatology , immunology , chronic hepatitis , virus
To evaluate the outcomes in biological treatment and quality of life of psoriatic patients with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) compared to pegylated interferon-2α plus ribavirin (P/R) therapy.